What is Aptose Bioscienc's earnings per share (EPS)?

Aptose Bioscienc (APTOF) reported diluted earnings per share of $-10.41 for fiscal year 2025. This represents a 71.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aptose Bioscienc Financials

APTOF

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Aptose Bioscienc (APTOF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 22/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Aptose Bioscienc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Aptose Bioscienc generates $0.86 in operating cash flow (-$22.0M OCF vs -$25.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$25.5M

YoY-0.1%

Aptose Bioscienc reported -$25.5M in net income in fiscal year 2025. This represents a decrease of 0.1% from the prior year.

EPS (Diluted)

$-10.41

YoY+71.4%

Aptose Bioscienc earned $-10.41 per diluted share (EPS) in fiscal year 2025. This represents an increase of 71.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$22.0M

YoY+38.9%

Aptose Bioscienc generated -$22.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 38.9% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

YoY+27.2%

Aptose Bioscienc had 3M shares outstanding in fiscal year 2025. This represents an increase of 27.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$11.3M

YoY-24.9%

5Y CAGR-17.3%

Aptose Bioscienc invested $11.3M in research and development in fiscal year 2025. This represents a decrease of 24.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY+0.0%

5Y CAGR-42.4%

Aptose Bioscienc invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

APTOF Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.3M-24.9%	$15.1M-54.6%	$33.3M+35.6%	$24.5M-46.7%	$46.0M+57.0%	$29.3M
SG&A Expenses	$13.4M+20.0%	$11.2M-28.5%	$15.6M+7.4%	$14.5M-25.4%	$19.5M-26.5%	$26.5M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	N/A	N/A	N/A	N/A
Net Income	-$25.5M-0.1%	-$25.4M+50.3%	-$51.2M-22.4%	-$41.8M+36.0%	-$65.4M-18.3%	-$55.2M
EPS (Diluted)	$-10.41+71.4%	$-36.38	$-227.43	$-6.80	$-0.73	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0	$0	$0	N/A	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.2M-33.1%	$3.3M+39.5%	$2.4M	N/A	$4.7M+6.5%	$4.4M-31.5%	$6.4M	N/A
SG&A Expenses	$2.7M-25.3%	$3.6M+17.0%	$3.1M	N/A	$2.3M-22.8%	$2.9M-11.6%	$3.3M	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	-$212K-92.7%	-$110K-31.0%	-$84K	N/A	$12K-87.1%	$93K-23.1%	$121K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.1M+27.3%	-$7.0M-27.1%	-$5.5M	N/A	-$7.0M+4.1%	-$7.3M+24.8%	-$9.6M+19.4%	-$12.0M
EPS (Diluted)	$-2.01+27.2%	$-2.76-5.7%	$-2.61	N/A	$-11.33+12.8%	$-12.99+41.0%	$-22.02	$-1.57

APTOF Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$10.1M-22.0%	$13.0M-74.5%	$51.0M-38.2%	$82.5M-34.6%	$126.3M
Current Assets	N/A	$9.5M-19.9%	$11.9M-76.0%	$49.5M-39.4%	$81.7M-34.7%	$125.1M
Cash & Equivalents	N/A	$6.2M-33.5%	$9.3M-75.0%	$37.0M-5.5%	$39.1M-66.7%	$117.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$14.7M-7.7%	$15.9M+19.6%	$13.3M+60.3%	$8.3M+12.8%	$7.3M
Current Liabilities	N/A	$4.5M-70.7%	$15.3M+24.3%	$12.3M+50.3%	$8.2M+20.0%	$6.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	-$4.5M-56.6%	-$2.9M-107.7%	$37.7M-49.2%	$74.2M-37.6%	$118.9M
Retained Earnings	N/A	-$541.0M-4.9%	-$515.5M-11.0%	-$464.3M-9.9%	-$422.5M-18.3%	-$357.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$6.3M+13.4%	$5.6M-25.1%	$7.5M-26.3%	$10.1M-7.3%	$10.9M-0.2%	$10.9M-14.4%	$12.8M-1.5%	$13.0M
Current Assets	$3.8M+15.5%	$3.3M-53.1%	$7.0M-26.9%	$9.5M-6.9%	$10.2M+0.7%	$10.2M-14.1%	$11.8M-0.6%	$11.9M
Cash & Equivalents	$613K+10.8%	$553K-88.3%	$4.7M-22.9%	$6.2M-22.7%	$8.0M-4.4%	$8.3M+13.4%	$7.3M-20.6%	$9.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$25.8M+29.2%	$20.0M+34.3%	$14.9M+1.3%	$14.7M-26.9%	$20.1M+52.9%	$13.1M+3.7%	$12.7M-20.3%	$15.9M
Current Liabilities	$7.1M-21.3%	$9.0M+42.5%	$6.3M+41.1%	$4.5M-54.1%	$9.8M-23.2%	$12.7M+4.7%	$12.1M-20.5%	$15.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$19.4M-35.3%	-$14.4M-94.4%	-$7.4M-62.7%	-$4.5M+50.3%	-$9.1M-319.8%	-$2.2M-1688.3%	$137K+104.7%	-$2.9M
Retained Earnings	-$558.7M-0.9%	-$553.6M-1.3%	-$546.5M-1.0%	-$541.0M-0.3%	-$539.4M-1.3%	-$532.4M-1.4%	-$525.2M-1.9%	-$515.5M

APTOF Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$22.0M+38.9%	-$36.0M+19.3%	-$44.6M-38.0%	-$32.3M+25.4%	-$43.3M-27.8%	-$33.9M
Capital Expenditures	$5K0.0%	$5K-82.8%	$29K+20.8%	$24K-88.7%	$212K+168.4%	$79K
Free Cash Flow	-$22.0M+38.9%	-$36.0M+19.4%	-$44.6M-37.9%	-$32.3M+25.7%	-$43.5M-28.1%	-$34.0M
Investing Cash Flow	$18K0.0%	$18K-99.8%	$10.0M-66.9%	$30.1M+185.4%	-$35.2M-378.8%	$12.6M
Financing Cash Flow	$19.4M-42.0%	$33.4M+383.6%	$6.9M+5856.9%	$116K-48.7%	$226K-99.6%	$58.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$7.4M-24.7%	-$5.9M-112.6%	-$2.8M+65.3%	-$8.1M+22.3%	-$10.4M-79.6%	-$5.8M+50.9%	-$11.8M-27.0%	-$9.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$9.3M
Investing Cash Flow	$0	$0	$0	$0	$0-100.0%	$2.0M+200.9%	-$2.0M-202.7%	$1.9M
Financing Cash Flow	$7.8M+210.0%	$2.5M+201.6%	$829K-87.8%	$6.8M-32.0%	$10.0M+110.5%	$4.8M-59.9%	$11.8M+1287.2%	$854K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APTOF Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	-110.8%-22.8pp	-88.0%-41.6pp	-46.5%
Return on Assets	N/A	-251.1%+143.1pp	-394.2%-312.3pp	-82.0%-2.8pp	-79.2%-35.4pp	-43.8%
Current Ratio	N/A	2.13+1.3	0.78-3.3	4.03-6.0	10.00-8.4	18.36
Debt-to-Equity	N/A	-3.23+2.2	-5.48-5.8	0.35+0.2	0.11+0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	-7036.5%	N/A
Return on Assets	-80.8%+45.2pp	-126.0%-51.7pp	-74.2%	N/A	-63.6%+2.6pp	-66.2%+9.1pp	-75.3%+16.7pp	-92.0%
Current Ratio	0.53+0.2	0.36-0.7	1.10-1.0	2.13+1.1	1.05+0.2	0.80-0.2	0.97+0.2	0.78
Debt-to-Equity	-1.33+0.1	-1.39+0.6	-2.01+1.2	-3.23-1.0	-2.20+3.8	-6.03-98.4	92.40+97.9	-5.48
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nascent Biotech NBIO

$3.3M

Eastgate Biotech ETBI

$3.2M

Zelira Therapeutics Limited ZLDAF

$3.0M

Mosaic Immunoengineering Inc CPMV

$5.0M

Avenue Therapeutics Inc ATXI

$2.8M

Frequently Asked Questions

Is Aptose Bioscienc profitable?

No, Aptose Bioscienc (APTOF) reported a net income of -$25.5M in fiscal year 2025.

What is Aptose Bioscienc's free cash flow?

Aptose Bioscienc (APTOF) generated -$22.0M in free cash flow during fiscal year 2025. This represents a 38.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Aptose Bioscienc's operating cash flow?

Aptose Bioscienc (APTOF) generated -$22.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aptose Bioscienc's capital expenditures?

Aptose Bioscienc (APTOF) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Aptose Bioscienc spend on research and development?

Aptose Bioscienc (APTOF) invested $11.3M in research and development during fiscal year 2025.

How many shares does Aptose Bioscienc have outstanding?

Aptose Bioscienc (APTOF) had 3M shares outstanding as of fiscal year 2025.

Are Aptose Bioscienc's earnings high quality?

Aptose Bioscienc (APTOF) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Aptose Bioscienc?

Aptose Bioscienc (APTOF) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.